Fondazione European Myeloma Network Italy O.N.L.U.S. — Sponsor Intelligence | 3 EU Trials

Filter these 3 trials by condition, phase, country and more.

3 Registered trials

0 Recruiting

2 Completed trials

1 Countries active

6 Unique IMPs

100% Results reported

Phase III

Phase II

100%

2 of 2 completed trials have published summary results (EU CTR Article 37 — 12-month obligation).

Top IMPs

3 total

MELFLUFEN FOR ELDERLY PATIENTS WITH RELAPSED MYELOMA Not authorised

2024-514652-33-00 Phase II 1 country DEXAMETHASONE SODIUM PHOSPHATE; MELPHALAN FLUFENAMIDE
A Trial for relapsed and relapsed/refractory multiple myeloma patients Ended

2023-506733-30-00 Phase II 1 country DARATUMUMAB; DEXAMETHASONE SODIUM PHOSPHATE; POMALIDOMIDE
A randomized trial that compares Carfilzomib - Lenalidomide - Dexamethasone (KRd) versus Lenalidomide - Dexamethasone (Rd) in new diagnosed … Ended

2024-513396-41-00 Phase III 1 country CARFILZOMIB; DEXAMETHASONE SODIUM PHOSPHATE; LENALIDOMIDE

Showing 1–3 of 3 trials